Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing challenges with rising competition in the obesity drug market. The company recently cut its full-year sales growth guidance for the second time in three months and announced a new CEO. This led to a 21% drop in its stock price on a single day.

Novo Nordisk, known for drugs like Ozempic and Wegovy, has a market capitalization of about $217.9 billion. However, its stock has tumbled 44.7% year-to-date, while the S&P 500 has seen gains. Novo’s stock is currently trading at a low valuation compared to its sector median and historical averages.

Despite posting strong first-quarter earnings, Novo Nordisk trimmed its full-year sales growth guidance due to challenges in the U.S. market. The company faces competition from compounding pharmacies producing copycat versions of its drugs, impacting sales.

Novo Nordisk recently completed a successful trial for its next-generation obesity drug, CagriSema, showing promising weight loss results. However, the company’s leadership changes and revised financial outlook have raised concerns about its future performance in the obesity drug market.

As Novo Nordisk prepares to release its Q2 earnings and undergo a leadership transition, analysts remain cautiously bullish on the stock. The consensus rating is a “Moderate Buy,” with an average price target of $71.75, suggesting potential upside of 47% from current levels.

Read more at Yahoo Finance: Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?